Papers
1
Total Citations
310
H-Index
1
About
Dr. Ana Cuenda is a leading figure in the field of cellular signaling, with a particular focus on the stress-activated protein kinase (SAPK) pathways, especially the p38 MAPK family. Her groundbreaking work has fundamentally advanced our understanding of how these kinases regulate inflammation and cellular stress responses. Among her most influential contributions is the characterization of the compound BIRB796, a potent inhibitor initially thought to target only p38α and p38β. In a highly cited 2005 study (310 citations), Cuenda demonstrated that BIRB796 also inhibits SAPK3/p38γ, albeit at higher concentrations, revealing critical nuances in kinase selectivity and drug action. This discovery has profound implications for the development of targeted therapies for inflammatory diseases, as BIRB796 has progressed to clinical trials. Through meticulous biochemical and in vivo analyses, Cuenda’s work has provided essential tools for dissecting the distinct roles of p38 isoforms, earning her recognition as a key contributor to signal transduction research. Her findings continue to guide both basic science and translational efforts in inflammation and cancer biology.
Research Focus
Key Achievements
Top Papers
- 1BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo310 citations · 2005